Abstract: The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups.

Abstract: 99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.

Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.

Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.

Abstract: 99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.

Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.

Abstract: Methods and compositions for detecting free radicals, the compositions being spin trapping compounds comprising a nitrone having a detecting moiety and optionally having a targeting moiety for targeting the nitrone to an organ, a cell, an organelle or a molecule of interest for directly detecting free radicals, especially free radicals in biological samples.

Abstract: The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups.

Abstract: 99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.

Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.

Abstract: Methods and compositions for detecting free radicals, the compositions being spin trapping compounds comprising a nitrone having a detecting moiety and optionally having a targeting moiety for targeting the nitrone to an organ, a cell, an organelle or a molecule of interest for directly detecting free radicals, especially free radicals in biological samples.

Abstract: Methods for treating cancers/tumors, including administering to a subject an effective amount of a mitochondria-targeted antioxidant alone or in combination with a chemotherapeutic agents. Likewise, methods for mitigating toxicity associated with a chemotherapeutic agent including administering an effective amount of a mitochondria-targeted antioxidant with a single or with multiple chemotherapeutic agents.

Abstract: It is disclosed here that HMG-CoA reductase inhibitors inhibit the proliferation and cause the death of breast cancer cells by inducing the expression of inducible nitric oxide synthase (iNOS) to promote intracellular nitric oxide formation, which the inventors found to be accomplished through the inhibition of protein geranylgeranylation. The disclosure here enables a new breast cancer treatment strategy that combines the inhibition HMG-CoA reductase or protein geranylgeranylation and the promotion of nitric oxide formation by iNOS.

Abstract: The inventors have purified the fluorescent product in the hydroethidine-based supeorxide detection assays and further identified the product as 2-hydroxyethidium. Methods for synthesizing 2-hydroxyethidium and for detecting and quantifying superoxide are provided.

Abstract: The inventors have purified the fluorescent product in the hydroethidine-based supeorxide detection assays and further identified the product as 2-hydroxyethidium. Methods for synthesizing 2-hydroxyethidium and for detecting and quantifying superoxide are provided.

Abstract: An antibody specific for homocystamide adducts is disclosed. In a preferred embodiment of the present invention, the antibody is used to evaluate the level of homocysteine in a biological sample.

Abstract: An antibody specific for homocystamide adducts is disclosed. In a preferred embodiment of the present invention, the antibody is used to evaluate the level of homocysteine in a biological sample.